Challenges Facing eInformed Consent
An effective consent process in today’s clinical environment involves more than an informed consent form that meets basic regulatory requirements. As research and resulting clinical trials become more complex, the ability to deliver targeted information to participants grows more difficult. Lack of understanding by participants can lead to noncompliance, expensive delays, and potential legal disputes.
As a result, sponsors are beginning to employ multifaceted approaches to participant communication in an attempt to deliver relevant study information in a user-friendly manner. In addition to simplified consent forms, computer animation, videos, and electronic/online consent represent some of the emerging trends regarding participant consenting.
On Wednesday, June 16, 2010, from 10:30 a.m. to 12:00 p.m., a panel discussion will be held about electronic consent entitled “eInformed Consent: Putting the Pieces Together.” This session will explore making a decision to use eConsenting, the steps to electronic consent usage with an emphasis on FDA guidelines regarding consent, the interaction with Institutional Review Boards, and their relationship to electronic consenting.
“The purpose of the session is to provide an overview regarding alternatives to paper-based consent forms,” said Linda Coleman, JD, Director of Regulatory Affairs at Quorum Review IRB, and a member of the panel discussion. “I think anyone that does clinical research and has used or is thinking about using electronic consent forms will be interested in this session.”
Coleman will discuss issues related to the IRB Review, including the challenges and benefits of electronic/online consenting.
“IRB’s need to review all information that will be presented to the potential subject including any audio, graphics, video, and screen shots in order to determine if the electronic/online content is appropriate and in compliance with applicable regulations,” Coleman said.
Her presentation will discuss the issues to consider before submitting an electronic consent form for IRB approval and what the IRB considers when evaluating these types of forms.
Susan Brink, PhD, President and CEO of ConsentSolutions, will discuss the advantages for both research candidates and sponsors of utilizing electronic informed consent (elC) technology to improve, manage, and streamline the consenting process and give an overview of the steps to be taken in implementing an e-consenting process for a clinical trial.
Additional members of the panel include Melissa Mau, eConsent, MS, Director, Clinical Research Core, Oral Health Research Institute, Indiana School of Dentistry who will talk about “eConsent: The Perfect Solution?” and Jonathan S. Helgott, MS, Consumer Safety Officer, CDRH, FDA, who will discuss the, “FDA Point of View.”
Related Articles
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
Reaching Diverse Patient Populations With Personalized Treatment Methods
January 20th 2025Daejin Abidoye, head of solid tumors, oncology development, AbbVie, discusses a number of topics around diversity in clinical research including industry’s greatest challenges in reaching diverse patient populations, personalized treatment methods, recruitment strategies, and more.
